Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -50.4%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $52M | $73M | $124M | $50M | $82M | $1.8B | — | — |
| Enterprise Value | $131M | $152M | $202M | $126M | $118M | $1.8B | — | — |
| P/E Ratio → | -0.72 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.45 | 0.64 | 0.73 | 0.22 | 0.22 | 3.27 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 100.0% | — |
| Operating Margin | — | — | — | — | — | — | -24379.7% | — |
| Net Profit Margin | — | — | — | — | — | — | -27346.4% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -50.4% | -50.4% | -37.5% | -53.0% | -48.6% | -37.0% | -25.1% | -80.1% |
| ROA | -30.6% | -30.6% | -25.2% | -38.6% | -40.9% | -33.8% | -23.0% | -68.1% |
| ROIC | -18.0% | -18.0% | -20.0% | -34.0% | -33.7% | -41.1% | -101.3% | — |
| ROCE | -23.3% | -23.3% | -25.8% | -41.6% | -40.5% | -35.6% | -21.4% | -81.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.75 | 0.75 | 0.51 | 0.38 | 0.22 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.69 | 0.46 | 0.34 | 0.10 | -0.07 | -0.83 | -1.10 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -9.08 | -9.08 | -7.36 | -29.16 | -118.62 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 39.53 | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 | 18.53 | 6.54 |
| Quick Ratio | 39.53 | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 | 18.53 | 6.54 |
| Cash Ratio | 15.72 | 15.72 | 14.35 | 14.24 | 7.96 | 10.98 | 18.20 | 6.26 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $7M | $7M | $6M | $5M | $6M | $6M |
Imminent liquidity exhaustion
Based on reported figures, TIL trades at a price-to-book ratio of 0.44, which, according to recent market data, suggests that investors are pricing the company significantly below its net asset value, likely reflecting deep skepticism regarding the viability of its remaining clinical pipeline and future capital access.
The lack of meaningful revenue or positive earnings renders traditional P/E or EV/EBITDA multiples irrelevant for assessing fundamental value. The current valuation appears to be driven by a liquidation-style discount, where the market assigns little to no value to the Co-Z platform, viewing the firm primarily as a distressed entity with limited remaining runway.
As reported in financial statements, the company's ROIC has consistently remained in negative territory, reaching -3.0% in 2026Q1, which indicates that the firm has failed to generate any productive return on the capital deployed into its now-shuttered manufacturing and clinical development programs over the last several years.
The persistent negative ROIC trend highlights the structural inability of the current business model to convert R&D spending into tangible economic value. This decay in capital returns is a direct consequence of the pivot away from the ITIL-168 program, which effectively rendered previous capital investments as sunk costs with no path to future recovery.
According to recent SEC filings, the company's current ratio of 39.87 appears artificially inflated by the rapid liquidation of assets, yet the absolute cash balance of $6.6 million suggests a precarious liquidity position that may be insufficient to sustain operations beyond the immediate near-term horizon.
While the high current ratio might suggest strong short-term coverage, it is a misleading artifact of the company's transition to a minimal asset base. Investors should monitor the actual cash burn rate, as the current liquidity buffer provides very little margin for error should clinical or regulatory hurdles necessitate further capital expenditures.
As indicated by historical data, the price-to-book ratio is the most commonly misapplied metric for TIL, as it obscures the reality that the company's book value is largely composed of intangible assets and cash that are being rapidly depleted to fund ongoing, non-revenue-generating operational losses.
Relying on P/B for a pre-revenue biotech firm ignores the fact that the 'book value' does not represent a stable asset base, but rather a shrinking pool of capital. A more appropriate focus would be the 'cash runway' or 'burn-adjusted enterprise value,' which better captures the existential risk inherent in the company's current financial trajectory.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TIL stock.
Instil Bio, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
Instil Bio, Inc.'s return on equity (ROE) is -50.4%. The historical average is -47.4%.
Based on historical data, Instil Bio, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.